Bayer (BMV:BAYN N) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BAYN N Panoramica delle azioni

Bayer Aktiengesellschaft, insieme alle sue filiali, opera come società di scienze della vita in tutto il mondo.

BAYN N analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	3/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Negoziato a 42.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 37.85% all'anno

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

Le azioni sono altamente illiquide

Bayer Aktiengesellschaft Concorrenti

Genomma Lab Internacional. de

BMV:LAB B

Mex$21.2b

UCB

ENXTBR:UCB

€31.1b

Otsuka Holdings

TSE:4578

JP¥4.5t

Galderma Group

SWX:GALD

CHF 18.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bayer
Prezzi storici delle azioni
Prezzo attuale dell'azione	€501.00
Massimo di 52 settimane	€805.00
Minimo di 52 settimane	€500.00
Beta	0.97
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	-54.94%
Variazione a 5 anni	-63.90%
Variazione dall'IPO	-72.37%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	BAYN N	MX Pharmaceuticals	MX Mercato
7D	0%	-1.8%	0.8%
1Y	n/a	-14.9%	3.9%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato BAYN N rispetto al settore MX Pharmaceuticals.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di BAYN N rispetto al mercato MX.

Volatilità dei prezzi

Is BAYN N's price volatile compared to industry and market?
BAYN N volatility
BAYN N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	4.1%
10% most volatile stocks in MX Market	5.9%
10% least volatile stocks in MX Market	2.7%

Prezzo delle azioni stabile: BAYN N non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di BAYN N nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1863	96,567	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft, insieme alle sue consociate, opera come società di scienze della vita a livello mondiale. Opera attraverso i segmenti Farmaceutico, Salute del consumatore e Scienza delle colture. Il segmento Farmaceutico offre prodotti da prescrizione principalmente per la cardiologia e la salute delle donne; specialità terapeutiche nei settori dell'oncologia, dell'ematologia e dell'oftalmologia; apparecchiature per la diagnostica per immagini e soluzioni digitali, mezzi di contrasto e terapia cellulare e genica.

Bayer Aktiengesellschaft Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bayer con la sua capitalizzazione di mercato?
BAYN N statistiche fondamentali
Capitalizzazione di mercato	Mex$627.35b
Guadagni(TTM)	-Mex$27.77b
Ricavi(TTM)	Mex$1.03t

0.6x

Rapporto P/S

-22.6x

Rapporto P/E

BAYN N è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BAYN N Conto economico (TTM)
Ricavi	€47.11b
Costo del fatturato	€19.98b
Profitto lordo	€27.13b
Altre spese	€28.40b
Guadagni	-€1.27b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 12, 2024

Utile per azione (EPS)	-1.29
Margine lordo	57.59%
Margine di profitto netto	-2.69%
Rapporto debito/patrimonio netto	126.5%

Come si è comportato BAYN N nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.4%

Rendimento attuale del dividendo

-9%

Rapporto di remunerazione

BAYN N Panoramica delle azioni

Premi

Analisi del rischio

Bayer Aktiengesellschaft Concorrenti

BMV:LAB B

Mex$21.2b

ENXTBR:UCB

€31.1b

TSE:4578

JP¥4.5t

SWX:GALD

CHF 18.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Recent updates

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New major risk - Dividend sustainability

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings released: EPS: €2.22 (vs €3.35 in 1Q 2022)

Upcoming dividend of €2.40 per share at 4.0% yield

Full year 2022 earnings released: EPS: €4.22 (vs €1.02 in FY 2021)

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Bayer Aktiengesellschaft (XTRA:BAYN) acquired Targenomix GmbH.

Bayer Aktiengesellschaft Extends Development Program for Investigational Product Elinzanetant with Phase III Study in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week

Cinven Limited completed the acquisition of Environmental Science Professional business from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data from Innovative Science At ESMO Congress 2022

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

Bayer Launches ForGround

U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Second quarter 2022 earnings released: €0.30 loss per share (vs €2.38 loss in 2Q 2021)

Bayer Aktiengesellschaft (XTRA:BAYN) signed a shareholders agreement to acquire 65% stake in CoverCress Inc. from Bunge Ventures and Chevron U.S.A. Inc.

Rendimenti per gli azionisti